Tag Archives: embargo

FDA creates embargo policy in response to reporter concerns

Pia Christensen

About Pia Christensen

Pia Christensen (@AHCJ_Pia) is the managing editor/online services for AHCJ. She manages the content and development of healthjournalism.org, coordinates social media efforts of AHCJ and assists with the editing and production of association guides, programs and newsletters.

The Food and Drug Administration has adopted a policy on embargoes that permits reporters to share embargoed information with outside sources, provided the sources agree to uphold the embargo.

The policy explicitly supports embargoes as a way for reporters to add depth and detail to their stories, and conforms to common practice among medical journals and other sources of complex information.

The policy was shared with AHCJ this week after complaints from the organization earlier this year. In January, the FDA barred reporters from interviewing experts about new regulations on medical devices until the embargo lifted. AHCJ wrote to the FDA that such an approach created obstacles to serious journalism.

In an embargo, the group releasing information chooses the time and date that it will be made public, and reporters get an advance look as long as they agree to delay publication or broadcast until that time. Reporters are willing to do this because it allows time digest the information and seek comments from experts.

In a letter this week to AHCJ, the FDA outlined its policy going forward:

“A journalist may share embargoed material provided by the FDA with non-journalists or third parties to obtain quotes or opinions prior to an embargo lift provided that the reporter secures agreement from the third-party to uphold the embargo.”

The letter, from Meghan H. Scott, FDA’s acting associate commissioner for external affairs, said the FDA did not previously have a policy on embargoed news. After AHCJ’s inquiry, she wrote, the media staff met with AHCJ members, other journalists, and editors of medical and scientific journals as it worked to develop a policy.

“The FDA is committed to a culture of openness in its interaction with the news media and the public,” Scott wrote to Charles Ornstein, AHCJ president, and Felice Freyer, chair of AHCJ’s Right to Know Committee.

She specified that the FDA may provide embargoed information when:

  • the issue is not related to regulatory or enforcement issues and does not contain confidential, commercial information; and
  • the subject is complex or technical and early access to materials and subject matter experts will help reporters prepare their articles in a timely, accurate manner with the context needed to understand the material.

“We’re grateful that the FDA media staff took the time to study the issue and develop a suitable policy,” Freyer said. “The results are clear rules that are reasonable and workable – and a step forward in improving relations between the FDA and the media.”

AHCJ asks FDA to re-evaluate embargo policy

Pia Christensen

About Pia Christensen

Pia Christensen (@AHCJ_Pia) is the managing editor/online services for AHCJ. She manages the content and development of healthjournalism.org, coordinates social media efforts of AHCJ and assists with the editing and production of association guides, programs and newsletters.

The Association of Health Care Journalists has sent a letter to FDA officials asking them to re-examine a policy that prohibits reporters from sharing embargoed materials with sources before the embargo lifts for the purpose of obtaining outside comment and context. As AHCJ notes, this highly unusual policy severely limits the ability of reporters to give readers the full story of a federal agency.

From the letter:

The restriction imposed on the medical-device announcement rewrote a longstanding compact between reporters and various public and scientific organizations. It also hampered or delayed reporters’ ability to fully inform the public about what the FDA is doing with taxpayers’ money. The early reports on the medical device approval process were brief and uninformative as a result.

Read the complete letter.

We will be sure to update readers if AHCJ receives a response from the FDA.

Policy lets many see study but restricts reporting

Pia Christensen

About Pia Christensen

Pia Christensen (@AHCJ_Pia) is the managing editor/online services for AHCJ. She manages the content and development of healthjournalism.org, coordinates social media efforts of AHCJ and assists with the editing and production of association guides, programs and newsletters.

On his new blog, Embargo Watch, Ivan Oransky, M.D., writes about an embargo policy that restricts journalists from writing about papers even when they are widely available to doctors, medical schools and hospitals.

Oransky, who is treasurer of AHCJ’s board and executive editor of Reuters Health, has written about embargoes before for Covering Health and TheScientist.com, questioning whether embargoes are serving the public, the scientific journals or journalists.

In this case, The American Journal of Respiratory and Critical Care Medicine placed an embargo on a study it made available “through HighWire, a Stanford University service that many publishers use to make electronic versions of their journals available.”

This was a new one for me. Embargoed papers not being available to anyone but the press, sure. But available to many doctors — and anyone doctors showed them to — for two weeks before we could write about them?

Oransky discussed the policy with the director of communications and marketing at the American Thoracic Society, which publishes AJRCCM, and reports on the response from him as well as from other public relations professionals and reporters.

One particularly interesting comment points out that investors are likely seeing studies release on HighWire, perhaps giving some an unfair advantage financially.

Tech journalists question future of embargoes

Andrew Van Dam

About Andrew Van Dam

Andrew Van Dam of The Wall Street Journal previously worked at the AHCJ offices while earning his master’s degree at the Missouri School of Journalism, and he has blogged for Covering Health ever since.

At last week’s “Embargo 2010: An Industry Conversation on Future Rules of Media Engagement,” tech journalists convened to discuss the viability of embargoes in an increasingly fluid media universe.

arrington
TechCrunch founder and editor Michael Arrington. Photo by jdlasica via Flickr.

Update: Follow the debate as it evolves on Twitter, either on this handy site or with the #embargo2010 hashtag.

The discussion seems to have been spurred by the anti-embargo grandstanding of TechCrunch founder and editor Michael Arrington, who canceled a planned appearance on the panel despite his well-publicized penchant for breaking embargoes. Threatened by embargo scofflaws like Arrington, many seemed to believe the embargo system was on its way out, and they saw a number of possible replacements. The consensus centered around two options:

  • Press conferences: This is already the prevailing model in the UK. Everyone gets the information at once, though a big conference is announced, there’s a general impression that somebody, somewhere will find a way to get the info early anyway. The downside, of course, is that folks don’t get as much time to prep their reports.
  • Exclusives: For the lucky outlet, exclusives are great. They get plenty of time to prepare and a jump on the story. They’re not as popular with everyone else, for obvious reasons.

Update: Read BayNewser’s E.B. Boyd’s recap (complete with photos) here. Boyd emphasizes the interplay between public relations professionals and journalists.

Tech versus health

Web PR man Shel Holtz rebuts Arrington’s anti-embargo stance, claiming that tech journalism is a special case and that, in other arenas (he specifically cites health journalism), they are going nowhere. His post includes audio from an embargo-related conversation with Mayo Clinic media relations chief Karl Oestreich.

Related

AHCJ lodges protest over handling of embargo

Pia Christensen

About Pia Christensen

Pia Christensen (@AHCJ_Pia) is the managing editor/online services for AHCJ. She manages the content and development of healthjournalism.org, coordinates social media efforts of AHCJ and assists with the editing and production of association guides, programs and newsletters.

The Association of Health Care Journalists has followed up on concerns about how an embargo was handled earlier this month by several federal agencies and a medical journal.

The organization sent letters this week to several federal agencies and a medical journal objecting to the uneven handling of embargoed news. The letters were addressed to officials at the National Institute of Mental Health, the Department of Health and Human Services, the Centers for Disease Control and Prevention and the American Academy of Pediatrics to protest the recent handling of embargoes on two autism studies. AHCJ is asking the agencies and academy to clarify embargo policies, saying that once an embargo is broken – once the news is out in any public forum, whether it’s a radio report, a public meeting, a Web site or a newspaper – the embargo must be lifted.

Read the full press release and the letters that were sent:

Autism news raises question: When is an embargo not an embargo?

Andrew Van Dam

About Andrew Van Dam

Andrew Van Dam of The Wall Street Journal previously worked at the AHCJ offices while earning his master’s degree at the Missouri School of Journalism, and he has blogged for Covering Health ever since.

Are embargoes yet another quaint tradition that, like so many before it, has been pushed into obsolescence by the weight of the Internet? Do so many people have access to so much information they can share so easily that artificial restrictions on publication are meaningless?

Consider: In a Friday press conference, the Department of Health and Human Services discussed, under embargo, highly newsworthy data indicating a much higher than expected prevalence of autism in the United States. HHS didn’t mention, however, that in an earlier call it had already given the most newsworthy part of that information to members of the “autism community,” and had not restricted them from publishing the info. The incident raises serious questions about giving special interests privileged access to data at the expense of major media outlets, as well as the validity of embargoes in an era of increasing media fluidity.

Routine embargo?

Friday, at 3 p.m., HHS held a press conference announcing (among other things) that according to a CDC study, the prevalence of autism spectrum disorders, previously thought to be about 1 in every 150 children, is actually closer to 1 in every 100 children. This news, big enough that it led Monday’s health coverage, was embargoed until Monday because it reached conclusions similar to Health Resources and Services Administration (HRSA) findings that would be published in the journal Pediatrics that day.

There is some confusion as to where the embargo originated, as a Pediatrics representative said the journal only enforced an embargo of the HRSA study, and that anybody could have published the results of the CDC study. We are still awaiting a CDC response and more information from AAP, but have talked to representatives of the National Institute of Mental Health (NIMH) and this much, at least, is clear: As applied, the embargo covered both studies and every bit of data released to journalists. It was not, however, applied to information about the CDC study released in the autism community call.

“Both the CDC overview and the HRSA study were embargoed, because the subject nature was obviously so similar,” NIMH spokesman Jim McElroy said. “It just wouldn’t be appropriate to not have the CDC following the same set of guidelines as the HRSA study as it relates to the embargo.”

Special access for special interests

The 2 p.m. autism community call, a hastily organized affair for which invitations went out just hours beforehand, featured a brief appearance by HHS Secretary Kathleen Sebelius and gave autism advocates a broad overview of the CDC study, McElroy said. Because few specifics were discussed, the study’s broad conclusion (that the prevalence of autism spectrum disorders was now thought to be nearer to 1 in 100 children) was not under embargo.

McElroy again:

“The embargo was not in place for the advocacy groups but that’s why it was a far more general overview approach on the part of NIMH, HRSA and CDC… whereas with media it was clearly understood that an embargo was in place so media had the opportunity to ask questions.”

“The advocacy groups are very different by nature.. from media outlets whose job is to disseminate information. It’s two very different audiences and that’s why the embargo certainly is in place.”

In other words, the autism community got less information, but they were allowed to do as they pleased with what they got. The media, on the other hand, got much more information, but were not allowed to publish any of it, not even that part which had been given to the autism community without restrictions.

Autism advocates run with the news

Those on the “autism community” call wasted no time in running with the info they’d learned. For example, Dan Olmsted immediately posted the key stat on Age of Autism, and David Kirby posted a more thorough breakdown on Age of Autism and The Huffington Post soon after. About.com also posted the data (with a reference to the Pediatrics article, even), though it seems to have been taken down since (It’s still indexed in Google news).

Adventures in Autism blogger Ginger Taylor joined the call as well; her Friday post reveals a few key facts about the discussion.

“The conference call was not announced to the press or public, but merely in an e-mail sent out at 9 a.m. inviting around 50 people in the autism community (almost exclusively friendly to the administration) to the 2 p.m. call with a ‘sorry for the short notice,’” Taylor wrote.

Journal doesn’t budge

Meanwhile, Pediatrics didn’t drop the embargo. In a brief call Tuesday morning Susan Martin, American Academy of Pediatrics’ director of media relations, said that stories like the Age of Autism and Huffington Post pieces hadn’t broken Pediatrics‘ embargo because they only reported on the similar study to be published by the CDC, and not specifically on the journal’s embargoed article, “Prevalence of Parent-Reported Diagnosis of Autism Spectrum Disorder Among Children in the US, 2007.” Martin did acknowledge that About.com had broken the embargo.

Readers take “tardy” media to task

The comments on Kirby’s Huffington Post entry show just how much of a debacle the embargo was for major media outlets. Readers didn’t understand the media’s hands were tied, they just knew that major outlets weren’t reporting on what looked like big news. Here are the most telling entries:

“Thanks to HuffPo for covering the autism issues that are being ignored by so many.”
–Theresa Conrick (Oct. 4)

“I sent this link to all TV news stations in our viewing area,both newspapers and the most popular Newstalk..­…silence­.”
–KFuller (Oct. 4)

“Stakeholders are just crying this weekend that no news source picked up this story. Thank you from the bottom of my heart Huffington Post and David Kirby.”
–TannersDad (Oct. 4)

The fallout: Do embargoes work anymore?

In the case of the bungled HHS autism release, mainstream outlets with explicit standards and institutional policies were hamstrung while less-established outlets nimbly skipped out front of a major story. It’s a somewhat unique situation that underscores the growing weakness of the embargo process.

Do embargoes work when they don’t apply to everyone equally? What about when they’re not followed by everyone? Is it “good enough” to keep mainstream media off the news while it multiplies with impunity throughout the blogosphere?

A related consideration: How big must an embargo-breaker be before everyone else follows suit? About.com, for example, gets more American traffic than any media outlet but CNN, ESPN and The New York Times and is the 27th most popular site among American Web users. It’s even owned by The New York Times Company, though the independently contracted “guide” who posted the news wasn’t under the control of the Times‘ editorial staff, of course. Despite all that, About.com still wasn’t considered influential enough to have killed the embargo.

Everybody needs to be under the same rules

AHCJ president and ProPublica senior reporter Charles Ornstein said that “If they’re going to be sharing information, it should be shared with the premise that everybody’s under the same rules.”

“I think it’s unfair to hold an embargoed briefing for the media and a non-embargoed briefing for advocates,” Ornstein said. “In a way, I think this punishes the media for abiding by embargoes in an era where information is easily shared by blog posts and by Twitter. When information enters the public domain, embargoes should be lifted.”

“While many people believe that embargoes play a vital role, events like this should cause us to make sure they’re fair to the media, and, even more than that, ask whether they help or hinder the process of conveying information to our readers, viewers and listeners,” Ornstein said.

UPDATE: Pediatrics explains why they didn’t lift embargo

Having made clear that the organization’s embargo only extended to the HRSA study, and not the CDC study discussed on the autism community call, the AAP’s Susan Martin provided AHCJ with the following statement:

The American Academy of Pediatrics (AAP) was notified of an embargo break by About.com on Saturday, Oct. 3, by a journalist for another news organization. The AAP evaluates embargo breaks on a case-by-case basis. In the About.com case, the AAP denied a request to lift the embargo early. Lifting the embargo over the weekend would have only added to the confusion, especially as the About.com post was removed as soon as the reporter learned she had broken the embargo, and many journalists had scheduled their news reports on the study to run Monday, Oct. 5.

In a similar vein, the just-distributed Pediatrics‘ media mailing for the Oct. 12 issue contained an “Editor’s Note” laying out the terms of AAP embargoes and reminding journalists of the sanctions the academy can impose upon outlets who violate those guidelines. The note also reminds folks that “Any decision to lift an embargo early is at the sole discretion of the AAP.”

UPDATE: CDC says no numbers were given to advocates

CDC spokeswoman Artealia Gilliard told AHCJ on Tuesday afternoon that everything in the 3 p.m. press call was under embargo, while nothing that would have been covered by that embargo was mentioned in the earlier call with the autism community. In particular, Gilliard said, no specific prevalence rate numbers were given out on the call.

“We basically said ‘On Monday, two studies will come out. They will update the prevalence estimate we previously had.’ … It didn’t actually have any of the information that was embargoed.”

Gilliard, who was on both calls, specified further: “I know they didn’t put out numbers in the advocacy call. I know we didn’t say 1 in 100. What we’ve been saying is ‘approximately 1 percent of children.’”

The difference between “1 in 100″ and “approximately 1 percent” is up for debate, but via e-mail, Adventures in Autism blogger Ginger Taylor outlined exactly how she and other autism-community bloggers were able to report the numbers without sitting in on the embargoed call: They’ve known them for a while.

Taylor first noted rumors of the new rate in a July blog post, David Kirby confirmed the rate and published conclusions of both the HRSA and CDC studies on the Huffington Post in August, and Tina Cruz noticed relevant changes to the CDC site late last month. So, even if the phrase “1 in 100″ was never uttered, those in the know were quick to connect the dots. Kirby confirmed this via e-mail, here’s an excerpt:

According to my notes for the community call, this is what Dr. Insel said:
“Preliminary analyses indicate an increase in estimated prevalence, to around 1% of children affected.”
1%, obviously, is 1 in 100.

Cruz also notes in the comments on this post that she noticed changes to the numbers on the CDC’s Web site.

So, while the cat may already have been out of the bag, the CDC did not release embargoed information on the autism call because, Gilliard said, “There’s no such thing as embargo with the general public. The only people who respect embargoes are journalists.”

In the autism advocate call, Gilliard said the CDC carefully walked the line between respecting Pediatrics‘ embargo and alerting parents and advocates to the upcoming changes as soon as possible.

When is an embargo not an embargo?

How about when a press release was never issued? None was available when the UK media reported results of a study about the effects of caffeine in pregnancy – before BMJ had a chance to publish online. Just the same, BMJ editor Fiona Godlee is a bit peeved. She acknowledges that, technically, there was no breach, but she maintains coverage still amounted to publicity before publication.

How did this happen? The UK’s Food Standards Agency, which funded the study, held a stakeholders meeting before BMJ issued its embargoed press release. “It was probably from this meeting that the study’s findings, and the government’s new guidelines on caffeine intake during pregnancy, were leaked,” she writes in an editorial. In this case, she continues, there was no harm done - the media got the story right.

Godlee was responding, in part, to an earlier BMJ blog post by FSA communications director Terrence Collis, who wrote the agency was less than “delighted” to get its study published in BMJ. Why? The FSA wants to show its research is high quality, but “we are even keener that the advice that reaches consumers is as clear as possible – and gets there as quickly as possible. This makes waiting around for journals to decide whether they are going to publish a real pain.” And that, he acknowledged, left time for leaks.

Some other thoughts about embargoes:

What do you think about embargoes and, specifically, this situation?